SCHEMBL19437435

SCHEMBL19437435

CCCNc1c(N)cc(C(N)=O)cc1OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
BPTF Q12830 1/20 0.45
MAPK1 P28482 1/20 0.44
HTT P42858 3/20 0.43
TSHR P16473 2/20 0.43
APOBEC3A P31941 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
NCOA1 Q15788 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
HDAC3 O15379 1/20 0.40
HDAC2 Q92769 1/20 0.40
GAA P10253 1/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PDE4A P27815 2/20 0.39
PDE4B Q07343 2/20 0.39
PDE4C Q08493 2/20 0.39
PDE4D Q08499 2/20 0.39
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22121045 0.86 TSHR (0.43) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL22135950 0.85 TSHR (0.40) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL29200564 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL19451673 0.83 HTT (0.43) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL19437440 0.83 MEN1 (0.43) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL28508495 0.83 PTGER4 (0.40) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL28515135 0.82 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2BPTFMAPK1HTT
SCHEMBL21158654 0.81 PARP15 (0.43) ALDH1A1SMN1; SMN2HTTTSHRLMNA
SCHEMBL22118789 0.81 MAPK14 (0.39) ALDH1A1SMN1; SMN2HTTTSHRGAA
SCHEMBL29240411 0.80 TSHR (0.49) ALDH1A1SMN1; SMN2BPTFMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112279835-B Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof 中国医学科学院药物研究所 2022-07-22 CN disclosed
US-10975287-B2 Heterocyclic amides useful as protein modulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2021-04-13 US disclosed
US-10975287-B2 Heterocyclic amides useful as protein modulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2021-04-13 US disclosed
CN-112279835-A Aromatic ring or aromatic heterocyclic imidazole compound, preparation method and pharmaceutical application thereof 中国医学科学院药物研究所 2021-01-29 CN disclosed
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-10-15 US disclosed
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-10-15 US disclosed
WO-2020132549-A1 STING HETEROCYCLE AGONISTS AND USES THEREOF NIMBUS TITAN, INC. (US) 2020-06-25 WO disclosed
WO-2020132566-A1 STING PYRAZOLE AGONISTS AND USES THEREOF NIMBUS TITAN, INC. (US) 2020-06-25 WO disclosed
EP-3440072-B1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-01-29 EP disclosed
EP-3440072-B1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-01-29 EP disclosed
EP-3440072-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2019-02-13 EP disclosed
WO-2017175156-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-12 WO disclosed
WO-2017175156-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS ARGLU1, G3BP1, G3BP2 ALDH1A1 3445/4885SMN1; SMN2 3690/4885BPTF 953/4885
US-10975287-B2 Heterocyclic amides useful as protein modulators ARGLU1, G3BP1, G3BP2 ALDH1A1 3445/4885SMN1; SMN2 3690/4885BPTF 953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.